Monopar Therapeutics Granted Rare Pediatric Disease Designation To ALXN1840 To Treat Wilson Disease

Monopar Therapeutics said the FDA granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), its late-stage candidate for treatment of a rare pediatric condition. The designation is a supportive regulatory milestone that can enhance the program’s development outlook, but it is unlikely to move the stock meaningfully by itself.

Analysis

Monopar Therapeutics said the FDA granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), its late-stage candidate for treatment of a rare pediatric condition. The designation is a supportive regulatory milestone that can enhance the program’s development outlook, but it is unlikely to move the stock meaningfully by itself.